Clinical trials
Advanced HR+/HER2- Breast Cancer clinical trials
Below are recruiting advanced hr+/her2- breast cancer clinical trials, each written for real people, not researchers. We’re tracking 71 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07281833RecruitingPhase 3
Testing capivasertib with hormone therapy for advanced breast cancer
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
AnderlechtAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Princeton, New JerseyAges 18 years+ - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07117630RecruitingPhase 2
A new drug combo for advanced breast cancer after standard treatment
This trial tests a new drug combination for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after standard treatments like CDK4/6 inhibitors and hormone therapy. It aims to see if the combination can help when other options have stopped working.
ShanghaiAges 18 years+ - NCT07088263RecruitingPhase 3
Adaptive Chemotherapy for Advanced Breast Cancer
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Newport Beach, CaliforniaAges 18 years+ - NCT06515470RecruitingPhase 1
Testing BTX-9341 for advanced breast cancer
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Gilbert, ArizonaAges 18 years+ - NCT06383767RecruitingPhase 3
A study of ESG401 for advanced HR+/HER2- breast cancer
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06033287Recruiting
Real-world study of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
Changsha, HunanAges 18 years+ - NCT06762483Recruiting
Blood test for gene changes in advanced breast cancer
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Milan, ItalyAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Jonesboro, ArkansasAges 18 years+ - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Los Angeles, CaliforniaAges 18–100 - NCT06255392RecruitingPhase 3
Fluzoparib with apatinib vs chemo for advanced breast cancer
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
Guangzhou, GuangdongAges 18–70 - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+
Hear when a new Advanced HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced hr+/her2- breast cancer?
- Yes. Clin2 currently lists 71 recruiting advanced hr+/her2- breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced hr+/her2- breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced hr+/her2- breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.